News Samsung Bioepis signs R&D agreement with Takeda South Korean firm looking to develop novel drugs
News Growth hormone could be filed without further trials, says O... Drug could be filed after "outlier" analysis.
News OPKO weekly growth hormone jab fails in phase 3 US biotech OPKO Health has said it will continue with clinical development of its long-acting human growth hormone product (hGH-CTP), even though it has failed in a late stage trial in adul
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.